TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Depression in Parkinson's Disease Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
inclusion criteria:~* Parkinson's disease without dementia.~* Depression.~* Males or females.~exclusion criteria:~* Psychosis~* Heart block

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- nortriptyline (Type: EXPERIMENTAL): drug
- paroxetine (Type: EXPERIMENTAL): drug
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* P. falciparum mono-infection~* Fever (axillary temperature ≥37.5⁰C) or history of fever in preceding 48 hours~* Age \>1 years (≥ 18 years at the Ethiopia site)~* G6PD normal as defined by the Biosensor (SD Biosensor, ROK) at ≥70% of the adjusted male median (AMM) for each site~* Written informed consent~* Able to comply with all study procedures and timelines~Exclusion Criteria:~* General danger signs or symptoms of severe malaria~* Anaemia, defined as Hb \<8g/dl~* Pregnant women as determined by Urine β-HCG pregnancy test~* Breast feeding women~* Known hypersensitivity to any of the drugs given~* Regular use of drugs with haemolytic potential~* Blood transfusion within the last 4 months

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PQ7 (Type: EXPERIMENTAL): high dose primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
- standard care (Type: NO_INTERVENTION): As per national guidelines for P. falciparum treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CT-011 MAb in DLBCL Patients Following ASCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient's age is 18 years or older, both genders.~2. Confirmed Diffuse Large B-cell Lymphoma, transformed follicular lymphoma, diffuse mixed cell lymphoma or primary mediastinal large cell lymphoma with B-cell lineage.~3. The lymphoma is chemosensitive.~4. The lymphoma did not progress since pre-transplant chemotherapy.~5. ECOG performance status 0-1.~Exclusion Criteria:~1. Serious other illness.~2. Active autoimmune disease.~3. Type 1 diabetes.~4. Known immune deficiency.~5. Clinical evidence of primary or secondary brain or spinal cord involvement by lymphoma.~6. Active bacterial, fungal, or viral infection.~7. Positive HIV, Hepatitis B surface antigen plus viremia, or Hepatitis C antibody plus viremia.~8. Pregnant or nursing (positive pregnancy test).~9. Other concurrent clinical study or investigational therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-011 (Type: EXPERIMENTAL): The monoclonal antibody termed CT-011 (currently, pidilizumab).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive breast cancer, meeting 1 of the following criteria:~  * SBR grade I-II disease (patients \< 65 years of age)~ * SBR grade I-III disease (patients \> 65 years of age)~* T2 (2-5 cm), T3, or T4B, and N0-1 disease~* No metastatic disease~* Breast lesion not amenable to breast-conserving resection~* No inflammatory breast cancer~* No prior breast cancer~* Hormone receptor status:~  * Estrogen receptor- and/or progesterone receptor-positive~PATIENT CHARACTERISTICS:~* Postmenopausal~* No other cancer within the past 5 years except for adequately treated skin carcinoma or carcinoma in situ of the cervix~* No contraindication to anti-hormonal treatment~* No psychological, familial, social, or geographical reasons that would preclude follow up~PRIOR CONCURRENT THERAPY:~* At least 8 days since prior hormone replacement therapy~* No concurrent anti-vitamin K treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (ANA) (Type: ACTIVE_COMPARATOR): Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.
- Arm B (FULV) (Type: EXPERIMENTAL): Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Field Application of Shanchol in Adults in Bangladesh

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Apparently healthy individuals~2. Age: 18-45 years~3. Sex: Both male and female~4. Consent: Written informed consent form for participation in the study~Exclusion Criteria:~1. History of chronic illness, such as TB, hypertension, chronic asthma, diabetes~2. Gastrointestinal disorder such as abdominal pain or cramps, loss of appetite, nausea, vomiting or diarrhoea in the past 7 days~3. Intake of any anti-diarrheal medicine in the past one week or antimicrobial therapy in the past two weeks.~4. Any febrile illness in the past 7 days.~5. Receiving killed oral cholera vaccine any time in the past, and any other live or killed enteric vaccine in the last 4 weeks.~6. Immunocompromising condition or receipt of blood or blood products or parenteral immunoglobulin preparation in the past 3 months.~7. Females of reproductive age who are pregnant at the time of vaccination and follow up (determined by verbal screening e.g last menstrual period (LMP)).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Shanchol stored at 2-8oC (Type: ACTIVE_COMPARATOR): Vaccines will be stored at 2-8oC before administration.
- Shanchol stored at 25oC (Type: EXPERIMENTAL): Vaccines will be stored at 25oC for 14 days before administration.
- Shanchol stored at 37oC (Type: EXPERIMENTAL): Vaccines will be stored at 37oC for 14 days before administration.
- Shanchol stored at 42oC (Type: EXPERIMENTAL): Vaccines will be stored at 42oC for 14 days before administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females (English or Spanish speaking) age ≥ 18 years with a history of AF in the last 30 days that was treated with normal rhythm restored.~* Ability to successfully use the AliveCor™ Heart Monitor, capture a baseline ECG, and transmit on the day of enrollment~* Demonstrated ability to receive, read, and send a text messages on the day of enrollment~* Willingness to complete the study questionnaires at baseline and 6 months~Exclusion Criteria:~* Documented permanent (chronic) AF~* Patient found to be in AF or other rhythm disturbances on the day of enrollment (i.e., they need to be clinically evaluated or treated)~* Unwillingness have their clinical data collected over the study period~* Unwillingness to receive and read cardiovascular text messaging three times a week.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iHEART (Type: EXPERIMENTAL): Participants will transmit daily ECGs using AliveCor for 6 months following cardioversion or ablation procedure to treat AF/AFL. Participants will also receive read-only behavioral altering messaging three times per week focusing on AF, cardiovascular risk factors, and healthy living.
- Usual Care (Type: NO_INTERVENTION): Participants will continue with usual care with their physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral and Peripheral Perfusion Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (ages 40-65) children of parent with documented Alzheimer's disease~Exclusion Criteria:~* Current use of cholesterol lowering medication~* History of liver disease~* History of adverse reaction to statin medications~* Elevated lab values (CK and creatinine)~* Use of medications that counteract with atorvastatin~* History of dementia~* Currently pregnant~* Use of large quantities of grapefruit juice (more than 1 quart/day)~* Current involvement in another investigational drug study~* Contraindications to MRI

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): 40mg Atorvastatin nightly for 4 months
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo nightly for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18 years~* Fulfill at least 4 of the 11 criteria for the ACR classification~* Any extra-renal flare with an SLEDAI\>6 and/or one BILAG A or 2 B~* Oral corticosteroids\>10 mg/day and HCQ \> 400 mg/day for at least 30 days prior to inclusion~Exclusion Criteria:~* Presence of active renal disease~* Previous intolerance or hypersensibility to any of the active components~* Active infection~* Unmeasurable levels of TMPT~* Pregnancy~* Presence of a severe flare that requires other immunosuppressive treatment for its control~* Any Psychiatric or social condition that did not ensure the patient´s follow-up and patient´s collaboration~* Previous treatment with EC-MPS or Azathioprine in the last 2 months~* Previous treatment with biological therapy in the last 3 months for anti-TNF therapy or in the last year for anti-CD20 therapy~* ALT or GPT \>120 UI/mL non-lupus related in the last 30 days~* Leucopenia \<1000x10E6 non-lupus related in the last 30 days~* Symptoms related to other medical conditions non-lupus related such as antiphospholipid syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- azathioprine (Type: ACTIVE_COMPARATOR): None
- Enteric-coated Mycophenolate Sodium (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of ST-elevation myocardial infarction (STEMI) or~* Patients with a diagnosis of non-STEMI or~* Patients with stable coronary artery disease ≥75 years of age undergoing angiography/PCI AND with at least one additional risk criterion~and~* A finalized coronary angiography/PCI (optional for sites in Bangladesh).~* Male or female subjects ≥18 years.~* Written informed consent.~Exclusion Criteria:~* Influenza vaccination during the current influenza season or anticipating to be vaccinated during the current influenza season.~* Indication for influenza vaccination for some indication other than myocardial infarction.~* Severe allergy to eggs or previous allergic reaction to influence vaccine.~* Suspicion of febrile illness or acute, ongoing infection.~* Hypersensitivity to the active substances or ingredients of Vaxigrip or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol.~* Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response.~* Inability to provide informed consent.~* Age below 18 years.~* Previous randomization in the IAMI trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: influenza vaccine (Type: EXPERIMENTAL): Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.
- Drug: placebo (Type: PLACEBO_COMPARATOR): Saline administered as a deep subcutaneous injection at one occasion per subject.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 3D Printed Models in Mohs Micrographic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing MMS at University Hospitals Cleveland Medical Center, Chagrin Highlands and Westlake Campus~* Capable of reading and completing all subjective questionnaires~Exclusion Criteria:~* Cannot complete the survey measures independently for any reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Education with 3D printed model (Type: EXPERIMENTAL): The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
- Verbal Counselling (Type: ACTIVE_COMPARATOR): Participants in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years~* Either sex~* Liver resection deemed clinically appropriate for management of metastatic colorectal cancer~* Duration between decision to perform liver resection and surgery greater than 2 weeks~* Ability to give written informed consent and follow study protocol~* Telephone contact possible~Exclusion Criteria:~* Neo-adjuvant chemotherapy for colorectal cancer (CRC) liver metastasis~* Chemotherapy for any cancer in the previous 3 months~* Known bleeding diathesis or anticoagulation therapy~* Fish or seafood allergy~* Use of fish oil supplements (eg. cod liver oil) and unwilling to stop for the duration of the study~* Pregnancy~* Non-aspirin non-steroidal anti-inflammatory (NSAID) or corticosteroid use~* Renal impairment (serum creatinine \>150)~* Active inflammatory disease (e.g. Inflammatory Bowel Disease, Rheumatoid Arthritis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 2 capsules twice daily
- Eicosapentaenoic acid free fatty acid (Type: ACTIVE_COMPARATOR): 2g daily (2 x 500mg capsules twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 or more years of age~* Lung Infection of Individual not Recently Hospitalized meeting the following criteria: Radiographically-confirmed pneumonia (new or progressive infection site of the lungs) consistent with bacterial pneumonia), AND Acute illness (≤ 7 days duration) with at least three of the following clinical signs or symptoms consistent with lung infection: New or increased cough, Purulent sputum or change in sputum character, Auscultatory findings consistent with pneumonia, Difficulty in breathing, short breath, or decreased partial pressure of oxygen in blood, Fever greater than 38ºC oral or body temperature lower than that required for normal body function(\< 35ºC), White blood cell count greater than or less than the normal, Greater than 15% immature neutrophils (bands) irrespective of white blood cell count, AND Moderate lung infection~* The subject must require initial hospitalization, or treatment in an emergency room or urgent care setting, by the standard of care~* The subject's infection would require initial treatment with intravenous antimicrobials~* Female subjects of child-bearing potential, and those who are fewer than 2 years post-menopausal, must agree to, and comply with, using highly effective methods of birth control while participating in this study~Exclusion Criteria:~* Lung Infection of Individual not Recently Hospitalized suitable for outpatient therapy with an oral antimicrobial agent~* Confirmed or suspected respiratory tract infections attributable to sources other than bacteria from the individuals not recently hospitalized(e.g., ventilator-associated pneumonia, hospital-acquired pneumonia, visible/gross aspiration pneumonia, suspected viral, fungal, or mycobacterial infection of the lung)~* Non-infectious causes of lung lesion (e.g., pulmonary embolism, chemical pneumonitis from aspiration, hypersensitivity pneumonia, congestive heart failure)~* Accumulation of pus in the pleural cavity~* Microbiologically-documented infection with a pathogen known to be resistant to ceftriaxone, or epidemiological or clinical context suggesting high likelihood of a ceftriaxone-resistant typical bacterial pathogen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 150 Years
- Healthy Volunteers: f

Study Arms:
- Ceftaroline (Type: EXPERIMENTAL): None
- Ceftriaxone plus placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients must have either failed to achieve an American College of Rheumatology 20 % (ACR20) response at Weeks 12 and 14 in C87050 \[NCT00160602\], or must have completed the entire Week 24 assessment of C87050 \[NCT00160602\] trial.~Exclusion Criteria:~* A diagnosis of any other inflammatory Arthritis (e.g. Psoriatic Arthritis or Ankylosing Spondylitis)~* A secondary, non-inflammatory type of Arthritis (e.g. Osteoarthritis or Fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of CDP870 on the patient's primary diagnosis of Rheumatoid Arthritis (RA)~* Any concomitant biological therapy~* Any experimental therapy, within or outside a clinical

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab Pegol (Type: EXPERIMENTAL): All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete